Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst ...

Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the ...

Arcturus Therapeutics believes it’s “highly unlikely” it will lose the promised government funding for its bird flu mRNA ...

Q4 2024 Earnings Call Transcript March 6, 2025 Arcturus Therapeutics Holdings Inc. misses on earnings expectations. Reported ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) missed earnings with its latest annual results, disappointing overly-optimistic forecasters. Unfortunately, Arcturus Therapeutics Holdings delivered a ...

Arcturus Therapeutics Holdings Inc is a biotechnology firm based in San Diego, California, specializing in the development of innovative mRNA medicines and vaccines. With a focus on addressing ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $58.25, a high estimate of $63.00, ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and ...

Arcturus Therapeutics shares have fallen roughly 6% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $15.97, a decrease of 58% in the last 12 months.

Learn more about whether Kymera Therapeutics, Inc. or Ultragenyx Pharmaceutical Inc. is a better investment based on AAII's ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...